...
首页> 外文期刊>Surgical Endoscopy >Is limited surgery justified in the treatment of T1 colorectal cancer?
【24h】

Is limited surgery justified in the treatment of T1 colorectal cancer?

机译:T1大肠癌的治疗是否合理?

获取原文
获取原文并翻译 | 示例
           

摘要

Surgical treatment of colorectal cancer (CRC) should be aimed primarily at achieving a combination of surgical-oncologic radicalness and the highest possible quality of life. In recent years, surgical therapy for T1 CRC has tended toward less radical interventions. The question regarding changes in survival and recurrence rates still is unanswered.A retrospective medical chart review of patients surgically treated in our department for T1 CRC from January 1990 to December 2010 (n = 223) was performed. Charts were reviewed for tumor-specific parameters, local recurrence, distant metastasis, and patient survival. The different treatment options used were strictly separated for a more detailed workup.Radical resection (RR) was performed for 57.1 %, local resection (LR) for 14.8 %, and an endoscopic approach (EA) for 28.1 % of the study population. After receipt of the histology report, 35.7 % of the patients initially resected nonradically underwent reoperation, mostly using RR. Seven patients experienced a local recurrence over time (3.6 %): one after initial RR, three after LR, and three after EA. Systemic recurrence occurred for nine patients (4.6 %) over time, six of whom had undergone initial RR. High-risk criteria were shown for 20 T1 CRCs. For 60 % (12/20) of the patients, initial RR was performed. Radical reoperation was performed for 75 % of the nonradically treated high-risk tumors. One high-risk patient without reoperation experienced metastatic disease over time. The 5-year overall survival rate was 87.2 %, itemized for the defined subgroups as follows: 83.9 % for RR, 82.8 % for LR, and 58.2 % for EA.Patients with T1 CRC had a distinctly higher incidence of local recurrence after EA or LR. Explicit workup in terms of risk classification is crucial to reducing the risk of local and systemic recurrence. A nonradical approach should be only a second option for patients with T1 CRC, namely, those solely in clearly low-risk situations or those with distinct comorbidities.
机译:结直肠癌(CRC)的外科治疗应主要旨在实现外科肿瘤学根治性和最高生活质量的结合。近年来,T1 CRC的外科治疗已趋向于不太激进的干预措施。关于生存率和复发率变化的问题仍未得到解答。我们对1990年1月至2010年12月在我科接受T1 CRC手术治疗的患者进行回顾性医学图表审查(n = 223)。检查图表以了解肿瘤特异性参数,局部复发,远处转移和患者生存率。严格分开使用了不同的治疗方案,以进行更详细的检查:根治性切除(RR)占57.1%,局部切除(LR)占14.8%,内窥镜检查(EA)占研究人群的28.1%。收到组织学报告后,最初采用非根治性切除术的患者中有35.7%的患者接受了再次手术,主要是使用RR。随着时间的推移,七名患者经历了局部复发(3.6%):一例在初始RR后,三例在LR后,三例在EA后。随着时间的流逝,有9名患者(4.6%)发生了系统性复发,其中有6名接受了初始RR。显示了20例T1 CRC的高风险标准。对于60%(12/20)的患者,进行了初始RR。进行根治性再手术的非根治性高危肿瘤占75%。一名没有再次手术的高危患者会随着时间的推移经历转移性疾病。 5年总生存率为87.2%,按定义的亚组分类如下:RR为83.9%,LR为82.8%,EA为58.2%。患有T1 CRC的患者在EA或EA后局部复发的发生率明显更高LR。在风险分类方面进行明确的检查对于降低局部和全身复发的风险至关重要。对于T1 CRC患者,即仅处于明显低风险情况或具有明显合并症的患者,非根治性治疗应仅是第二种选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号